The unauthorized transfer of controlled substances from legal sources to illicit markets or for personal use continues to plague the healthcare industry. Thirty percent of respondents in a recent study conducted by Bluesight Technologies said they knew of colleagues who diverted opioids. That is almost 20% over last year. This figure could, however, be due in part to more accurate reporting and/or better early identification of potential diverters rather than a higher rate of diversion.  To this point, the 2022 Diversion Trends Report found that many hospitals were conducting twice as many investigations resulting in more drug anomalies. The positive side to these figures is that hospitals are becoming more proactive with their detection.  By putting specific policies, procedures, and technology into place, your organization can join the fight to prevent diversion. Read more >